Literature DB >> 23865820

Need for objective and reproducible criteria in histopathological assessment of total mesorectal excision specimens: lessons from a national improvement project.

P Demetter1, T Vandendael, C Sempoux, N Ectors, C A Cuvelier, N Nagy, A Hoorens, A Jouret-Mourin.   

Abstract

AIM: Data on quality control of the pathologic evaluation of total mesorectal excision (TME) specimens are scarce. We aimed to assess differences between evaluation by local pathologists participating in PROject on CAncer of the REctum (PROCARE; a Belgian improvement project on rectal cancer) and by a review panel of experts.
METHOD: Based on photographic material and histopathology slides, a Review Committee of gastrointestinal expert pathologists re-evaluated the mesorectal plane, the tumour differentiation grade, the (y)pT stage and the tumour regression grade in 444 patients previously routinely assessed by local pathologists.
RESULTS: The surgical plane was reported in 89% of patients and the circumferential resection margin in 88% of patients by the local pathologist. The median number of lymph nodes harvested in patients undergoing neoadjuvant radiochemotherapy was 11 and 14 in the other patients. The Review Committee downgraded the surgical plane from (intra)mesorectal to intramuscular in 17% of patients, and upgraded it from intramuscular to (intra)mesorectal in 27%. Tumour differentiation grade, T stage and tumour regression grade differed between local pathologists and the Review Committee in 15%, 10% and 38%, respectively, of patients. T stage was upgraded, mainly from T2 to T3, in 8% of patients. Tumour regression was judged by the Review Committee to be less advanced in 15% of patients.
CONCLUSION: Acknowledging some shortcomings, this study gives a realistic view of clinical practice. There are differences in interpretation with regard to both macroscopic and microscopic analysis of TME specimens. These findings indicate a need for more objective and reproducible criteria in histopathology. Being aware of this is a first step for improvement. Colorectal Disease
© 2013 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  Total mesorectal excision; adenocarcinoma; rectum

Mesh:

Year:  2013        PMID: 23865820     DOI: 10.1111/codi.12362

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  3 in total

1.  Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer.

Authors:  Feby Ingriani Mardjuadi; Javier Carrasco; Jean-Charles Coche; Christine Sempoux; Anne Jouret-Mourin; Pierre Scalliet; Jean-Charles Goeminne; Jean-François Daisne; Thierry Delaunoit; Peter Vuylsteke; Yves Humblet; Nicolas Meert; Marc van den Eynde; Anne Moxhon; Karin Haustermans; Jean-Luc Canon; Jean-Pascal Machiels
Journal:  Target Oncol       Date:  2014-10-11       Impact factor: 4.493

Review 2.  Pathologic processing of the total mesorectal excision.

Authors:  Molly Campa-Thompson; Robert Weir; Natalie Calcetera; Philip Quirke; Susanne Carmack
Journal:  Clin Colon Rectal Surg       Date:  2015-03

3.  Uptake of Total Mesorectal Excision and Total Mesorectal Excision Grading for Rectal Cancer: A Statewide Study.

Authors:  Arielle E Kanters; Robert K Cleary; Shawn H Obi; Theodor Asgeirsson; Sarah K Evilsizer; Laurie G Fasbinder; Darrell A Campbell; Samantha K Hendren
Journal:  Dis Colon Rectum       Date:  2020-01       Impact factor: 4.412

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.